However, notably, dramatic successes were seen in these initial cohorts (e.g., Cornell reported a patient with metastatic urothelial carcinoma with a HER2 amplification, a rare aberration in this tumor, that had a complete response when given targeted HER2 therapy). Here, ERBB2 is linked to neoplasm.